You are here

Non-invasive Diagnostic Platform Development for Celiac Disease Remission Status

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI112125-01
Agency Tracking Number: R43AI112125
Amount: $244,699.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1551 Eastlake Avenue East, Suite 200
SEATTLE, WA 98102-7402
United States
DUNS: 832591544
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MARK RIEDER
 (206) 659-0067
 mrieder@adaptivebiotech.com
Business Contact
 CHAD ROBBINS
Phone: (206) 659-0067
Email: crobins@adaptivebiotech.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): The purpose of this proposal is to adapt a technology that we have developed for monitoring residual disease in leukemia patients to monitor residual autoimmune disease in Celiac Disease patients. Celiac disease hasa significant burden on quality of life, as it is one of the most frequent autoimmune diseases, with an estimated prevalence of approximately 1% in populations of European descent. The sole treatment for celiac disease is to adopt a gluten-free diet, which resolves acute symptoms and intestinal pathology in a large majority of patients. Approximately one in twenty celiac patients will develop refractory celiac disease, where intestinal inflammation persists after 12 months of adherence to a gluten free diet. Refractory celiac disease patients are at risk for an aggressive non-Hodgkin lymphoma that is without effective treatments. Refractory celiac disease diagnosis is made from a biopsy of the small intestine, so a non-invasive diagnostic tool that co

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government